{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T04:42:33Z","timestamp":1794285753086,"version":"4.9.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T00:00:00Z","timestamp":1597363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T00:00:00Z","timestamp":1597363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Oncomed Pharmaceuticals","award":["111"],"award-info":[{"award-number":["111"]}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1K23CA172691-01A1"],"award-info":[{"award-number":["1K23CA172691-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s10549-020-05817-w","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T18:04:01Z","timestamp":1597428241000},"page":"53-62","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":148,"title":["Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer"],"prefix":"10.1007","volume":"184","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0703-2772","authenticated-orcid":false,"given":"Jennifer R.","family":"Diamond","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Becerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Mita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"O\u2019Shaughnessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall","family":"Henner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann M.","family":"Kapoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob","family":"Stagg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailaja","family":"Uttamsingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer K.","family":"Brachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azeez","family":"Farooki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Mita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,14]]},"reference":[{"key":"5817_CR1","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","volume":"29","author":"F Cardoso","year":"2018","unstructured":"Cardoso F, Senkus E, Costa A et al (2018) 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)dagger. Ann Oncol 29:1634\u20131657","journal-title":"Ann Oncol"},{"key":"5817_CR2","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.bbcan.2019.07.002","volume":"1872","author":"M Scimeca","year":"2019","unstructured":"Scimeca M, Urbano N, Bonfiglio R et al (2019) Novel insights into breast cancer progression and metastasis: A multidisciplinary opportunity to transition from biology to clinical oncology. Biochim Biophys Acta Rev Cancer 1872:138\u2013148","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"5817_CR3","doi-asserted-by":"publisher","first-page":"1248012","DOI":"10.1126\/science.1248012","volume":"346","author":"H Clevers","year":"2014","unstructured":"Clevers H, Loh KM, Nusse R (2014) Stem cell signalling. An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control. Science 346:1248012","journal-title":"Science"},{"key":"5817_CR4","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nature03319","volume":"434","author":"T Reya","year":"2005","unstructured":"Reya T, Clevers H (2005) Wnt signalling in stem cells and cancer. Nature 434:843\u2013850","journal-title":"Nature"},{"key":"5817_CR5","doi-asserted-by":"publisher","first-page":"11717","DOI":"10.1073\/pnas.1120068109","volume":"109","author":"A Gurney","year":"2012","unstructured":"Gurney A, Axelrod F, Bond CJ et al (2012) Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci U S A 109:11717\u201311722","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5817_CR6","doi-asserted-by":"publisher","first-page":"e1700090","DOI":"10.1126\/sciadv.1700090","volume":"3","author":"MM Fischer","year":"2017","unstructured":"Fischer MM, Cancilla B, Yeung VP et al (2017) WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death. Sci Adv 3:e1700090","journal-title":"Sci Adv"},{"key":"5817_CR7","doi-asserted-by":"crossref","unstructured":"Smith DC, Rosen L.S., Chugh R, Goldman J.W., Xu L, Kapoun A, Brachman R.K., Dupont J, Stagg R.J., Tolcher A.W., Papadopoulos K.P. First-in-human evaluation of the human monoclonal antibody vantictumab (OMP-18R5; anti-Frizzled) targeting the WNT pathway in a phase I study for patients with advanced solid tumors. In American Society of Clinical Oncology (ASCO) Annual Meeting. J Clin Oncol 2013; 2540\u20132540.","DOI":"10.1200\/jco.2013.31.15_suppl.2540"},{"key":"5817_CR8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nm0207-133","volume":"13","author":"SR Goldring","year":"2007","unstructured":"Goldring SR, Goldring MB (2007) Eating bone or adding it: the Wnt pathway decides. Nat Med 13:133\u2013134","journal-title":"Nat Med"},{"key":"5817_CR9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"5817_CR10","doi-asserted-by":"publisher","first-page":"7490","DOI":"10.1158\/1078-0432.CCR-17-2157","volume":"23","author":"A Jimeno","year":"2017","unstructured":"Jimeno A, Gordon M, Chugh R et al (2017) A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors. Clin Cancer Res 23:7490\u20137497","journal-title":"Clin Cancer Res"},{"key":"5817_CR11","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.ygyno.2019.04.001","volume":"154","author":"KN Moore","year":"2019","unstructured":"Moore KN, Gunderson CC, Sabbatini P et al (2019) A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. Gynecol Oncol 154:294\u2013301","journal-title":"Gynecol Oncol"},{"key":"5817_CR12","doi-asserted-by":"publisher","first-page":"90","DOI":"10.4183\/aeb.2018.90","volume":"14","author":"D Grigorie","year":"2018","unstructured":"Grigorie D, Lerner UH (2018) The Crucial Role of the Wnt System in Bone Remodelling. Acta Endocrinol (Buchar) 14:90\u2013101","journal-title":"Acta Endocrinol (Buchar)"},{"key":"5817_CR13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nm.3074","volume":"19","author":"R Baron","year":"2013","unstructured":"Baron R, Kneissel M (2013) WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med 19:179\u2013192","journal-title":"Nat Med"},{"key":"5817_CR14","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1083\/jcb.200201089","volume":"157","author":"M Kato","year":"2002","unstructured":"Kato M, Patel MS, Levasseur R et al (2002) Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 157:303\u2013314","journal-title":"J Cell Biol"},{"key":"5817_CR15","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1359\/jbmr.040907","volume":"19","author":"SL Holmen","year":"2004","unstructured":"Holmen SL, Giambernardi TA, Zylstra CR et al (2004) Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6. J Bone Miner Res 19:2033\u20132040","journal-title":"J Bone Miner Res"},{"key":"5817_CR16","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ejca.2016.09.024","volume":"70","author":"D Miles","year":"2017","unstructured":"Miles D, Cameron D, Bondarenko I et al (2017) Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation. Eur J Cancer 70:146\u2013155","journal-title":"Eur J Cancer"},{"key":"5817_CR17","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1056\/NEJMoa072113","volume":"357","author":"K Miller","year":"2007","unstructured":"Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666\u20132676","journal-title":"N Engl J Med"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05817-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-020-05817-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05817-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:25:53Z","timestamp":1667780753000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-020-05817-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,14]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["5817"],"URL":"https:\/\/doi.org\/10.1007\/s10549-020-05817-w","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,14]]},"assertion":[{"value":"5 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards:"}},{"value":"CZ, RH, AMK, LX, SU, BS and RKB are present or former employees of OncoMed Pharmaceuticals. AF received consulting fees from OncoMed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with animals performed by any of the authors. All procedures performed in the studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was conducted according to ICH guidelines and all sites had IRB\/EC approval prior to enrolling patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Informed consent was obtained from all participants included in the study. All participants gave their informed consent in writing prior to inclusion in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Patients enrolled on the clinical provided consent for publication of results. This manuscript does not contain data from any individual person.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and\/or analyzed during the current study are not publicly available due to restrictions in the informed consent document signed by the patients enrolled in this trial.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}}]}}